1 - 2 2. The definition of "Section 11(a)(ii) Event" contained in Section 1.(a) of the Agreement is hereby deleted in its entirety and the following language be inserted in lieu thereof:Rights Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances
PREAMBLE:Separation Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Ohio
EV PRODUCTSSupply Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Pennsylvania
DAVID C. BUPP 5747 RUSHWOOD DRIVE DUBLIN, OHIO 43017 February 16, 1999Employment Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances
NEOPROBE CORPORATION March 31, 1999 The Aries Master Fund The Aries Domestic Fund, L.P. c/o Paramount Capital Asset Management, Inc. Attn: Michael S. Weiss 787 Seventh Avenue, 48th Floor New York NY 10019 RE: PREFERRED STOCK AND WARRANT PURCHASE...Preferred Stock and Warrant Purchase Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances
NEOPROBE CORPORATIONPreferred Stock and Warrant Purchase Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances
Exhibit 10.2.47 SCHEDULE IDENTIFYING OMITTED DOCUMENTS The only particular in which the attached agreement differs from the omitted agreements is the name of the employee who is a party to the agreements. The following are the employees who are...Severance Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Ohio
1 2 Warrants") equal to the number of Warrants issued at the First Closing; provided however, (i) the Company shall not be entitled to give the notice permitted by this Section 1.1(b) if the Market Price of the Common Stock (after adjustment for any...Preferred Stock and Warrant Purchase Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances • New York
1 2 securities sold as part of such Investment at an exercise price equal to one- hundred-ten percent (110%) of the price of such securities, exercisable until five (5) years from the date of issuance of such warrants. For the purposes of this...Financial Advisory Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances • New York
